Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

UK Biobank’s Chief Executive Officer and Principal Investigator, Professor Sir Rory Collins, has been selected to feature in the inaugural TIME100 2024 Health list.

This special issue of TIME magazine recognises the 100 most influential and innovative people in health this year from around the world. Appearing in this list alongside 99 other world leaders in health demonstrates the extraordinary impact of UK Biobank, which is led by Professor Collins, alongside his role as Head of Department.

Professor Collins said ‘It has been a privilege to guide UK Biobank over the last two decades as it has grown into a vital piece of the puzzle to improve public health. This accolade should really go to all 500,000 of UK Biobank’s incredible participants, without whom this one-of-a kind research resource would not exist.

‘TIME’s recognition reflects the enormous collective effort of the extraordinary teams at UK Biobank and the Nuffield Department of Population Health who, alongside others who appear in this first ever TIME100 2024 Health list, are helping to shape a better future for the health of people everywhere.’

Professor Collins took up the role of UK Biobank’s CEO and Principal Investigator in September 2005. UK Biobank has gone from strength to strength over the past 19 years, and was recently described as “one of the jewels in the crown of UK science” by the Secretary of State for Science, Innovation and Technology.

Rory has specialised in the establishment of large-scale epidemiological studies of the causes, prevention and treatment of heart attacks, other vascular disease, and cancer. He is a Fellow of the Academy of Medical Sciences and the Royal Society and was knighted in 2011 for his services to science.